Company intelligence / Profile preview

Poniard Pharmaceuticals, Inc.

Seattle, Washington, United Statesponiard.com ↗

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Poniard’s lead asset was picoplatin, a next-generation platinum chemotherapy designed to overcome resistance seen in standard platinum therapies. The pivotal SPEAR Phase III trial evaluated picoplatin as second-line therapy in small cell lung cancer. Additional trials included Phase II studies in metastatic colorectal and castration-resistant prostate cancers and a Phase I study of an oral formulation. Clinical data suggested improved safety over existing platinum drugs but the company did not achieve commercialization before becoming inactive/acquired.

Therapeutic areas: Oncology
Modalities: Small molecules (notably platinum-based chemotherapeutics)
Industry: Biotech

Drug pipeline

2 assets

picoplatin

1 more asset in the full pipeline.

Partnerships

Research collaboration with Scripps Florida on protein kinase inhibitors

Beyond the preview

Go deeper on Poniard Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poniard Pharmaceuticals, Inc..